XORTX Therapeutics (XRTX) Gains from Investment Securities (2021 - 2025)

XORTX Therapeutics (XRTX) posted Gains from Investment Securities of $26924.0 for Q4 2025, down 78.78% on a QoQ basis from $126880.5 in Q1 2022.

XORTX Therapeutics (XRTX) Gains from Investment Securities (2021 - 2025) Analysis & Trends

XORTX Therapeutics' Gains from Investment Securities history runs 3 years deep, the most recent figure standing at $26924.0 for Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,290.43 Bn	66,290.15 Bn	-
2	Nanobiotix	1,914.07 Bn	1,914.01 Bn	-
3	Akari Therapeutics	1,009.43 Bn	1,009.43 Bn	-
4	BeOne Medicines	467.97 Bn	463.18 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.73 Bn	115.48 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.42 Bn	61.67 Bn	3.31 Bn
7	Belite Bio	62.82 Bn	62.82 Bn	-
8	Argenx Se	56.00 Bn	50.82 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.51 Bn	34.50 Bn	959.66 Mn
10	XORTX Therapeutics	2.81 Bn	2.81 Bn	-

Download Data